Identification of a selective glucocorticoid receptor modulator that prevents both diet-induced obesity and inflammation.
van den Heuvel et al. • 2016 • Br J Pharmacol. 2016;173(11):1793-804.
© 2024 Corcept Therapeutics, Incorporated
Glucocorticoid antagonism limits adiposity rebound and glucose intolerance in young male rats following the cessation of daily exercise and caloric restriction.
Teich et al. • 2016 • Am J Physiol Endocrinol Metab. 2016;311(1):E56-68.
Effects of selective and non-selective glucocorticoid receptor II antagonists on rapid-onset diabetes in young rats.
Beaudry et al. • 2014 • PLoS One. 2014;9(3):e91248.
Discovery of a novel non-steroidal GR antagonist with in vivo efficacy in the olanzapine-induced weight gain model in the rat.
Hunt et al. • 2012 • Bioorg Med Chem Lett. 2012;22(24):7376-80.
Selective glucocorticoid receptor (GR-II) antagonist reduces body weight gain in mice.
Asagami et al. • 2011 • J Nutr Metab. 2011;2011:235389.
Selective glucocorticoid receptor (type II) antagonists prevent weight gain caused by olanzapine in rats.
Belanoff et al. • 2011 • Eur J Pharmacol. 2011;655(1-3):117-20.
The efficacy of mifepristone in the reduction and prevention of olanzapine-induced weight gain in rats.
Beebe et al. • 2006 • Behav Brain Res. 2006;171(2):225-9.
Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men.
Gross et al. • 2010 • Obesity (Silver Spring). 2010;18(12):2295-300.
Mifepristone treatment of olanzapine-induced weight gain in healthy men.
Gross et al. • 2009 • Adv Ther. 2009;26(10):959-69.
Glucocorticoid receptor expression in 20 solid tumor types using immunohistochemistry assay.
Block et al. • 2017 • Cancer Manag Res. 2017;9:65-72.